Neurocrine Biosciences (NBIX) was upgraded by Wolfe Research to "strong-buy".
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March [Yahoo! Finance]
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
Neurocrine Biosciences (NASDAQ:NBIX) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $160.00 price target on the stock.
Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.